Michael-John O’Connor, Director of Biochemical Services at BioPharmaSpec, discusses analysing biosimilars, glycosylated mAbs and PEGylated proteins with Lu Rahman.  LR: Outline the importance of bio-molecules in drug discovery. What is their potential within therapeutic development?    MJOC: The FDA’s recent approval of Biocon’s Semglee (long acting Insulin glargine) is the first example of an interchangeable biosimilar that can be substituted for its reference medicinal product, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!